Dose Escalation Study of PF-07209326 in Healthy Participants and Participants With Sickle Cell Disease
Public ClinicalTrials.gov record NCT04255875. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED EVALUATION OF SINGLE DOSES OF PF-07209326 IN HEALTHY PARTICIPANTS (SAFETY, TOLERABILITY, AND PHARMACOKINETICS [PK]) FOLLOWED BY AN OPEN LABEL, REPEAT DOSE EVALUATION IN SICKLE CELL DISEASE PARTICIPANTS (SAFETY, TOLERABILITY, PK AND EFFICACY)
Study identification
- NCT ID
- NCT04255875
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Pfizer
- Industry
- Enrollment
- 52 participants
Conditions and interventions
Conditions
Interventions
- PF-07209326 Biological
- Placebo Biological
Biological
Eligibility (public fields only)
- Age range
- 16 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 4, 2020
- Primary completion
- Jul 6, 2023
- Completion
- Jul 6, 2023
- Last update posted
- Dec 17, 2023
2020 – 2023
United States locations
- U.S. sites
- 16
- U.S. states
- 8
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| New Haven Clinical Research Unit | New Haven | Connecticut | 06511 | — |
| Howard University College of Medicine | Washington D.C. | District of Columbia | 20060 | — |
| Golisano Children's Hospital of Southwest Florida | Fort Myers | Florida | 33908 | — |
| Lee Health - Golisano Children's Hospital of Southwest Florida | Fort Myers | Florida | 33908 | — |
| Foundation for Sickle Cell Disease Research | Hollywood | Florida | 33023 | — |
| Foundation for Sickle Cell Disease Research | Hollywood | Florida | 33024 | — |
| Children's Healthcare of Atlanta - Egleston Hospital-Aflac Cancer and Blood Disorders Center | Atlanta | Georgia | 30322 | — |
| University of Illinois at Chicago Clinical Research Center | Chicago | Illinois | 60612 | — |
| University of Illinois at Chicago | Chicago | Illinois | 60612 | — |
| Prism Research LLC dba Nucleus Network | Saint Paul | Minnesota | 55114 | — |
| Columbia University Medical Center - Herbert Irving Pavilion | New York | New York | 10032 | — |
| CUIMC Research Pharmacy | New York | New York | 10032 | — |
| CUMC Research Pharmacy | New York | New York | 10032 | — |
| UT Physicians Comprehensive Sickle Cell Center Houston | Houston | Texas | 77004 | — |
| Memorial Hermann clinical research unit | Houston | Texas | 77030 | — |
| UT Physicians Comprehensive Sickle Cell Center Houston | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04255875, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 17, 2023 · Synced May 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04255875 live on ClinicalTrials.gov.